SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.
SAB Biotherapeutics has raised $85.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2026.
SAB Biotherapeutics's investors include RA Capital Management, Vivo Capital, Sanofi, RTW Investments, Commodore Capital.
SAB Biotherapeutics is headquartered in Sioux Falls, United States.
SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.
SAB Biotherapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"SAB Biotherapeutics — Funding & Investors." VCBacked, March 17, 2026, https://www.vcbacked.co/company/sab-biotherapeutics. Accessed August 13, 2026.
VCBacked. (2026). SAB Biotherapeutics — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/sab-biotherapeutics
{{cite web |title=SAB Biotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/sab-biotherapeutics |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated